Micromet to Report First Quarter 2011 Financial Results on May 10

BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review its first quarter 2011 financial results on Tuesday, May 10, 2011, at 8:30 AM ET.

To participate in the conference call, please dial 800-638-5495 (domestic) or 617-614-3946 (international) and reference the access code 69045420. The presentation will be available via webcast in the Investor and Media section of the Micromet website at www.micromet.com.

A replay of the call will be available from 11:30 AM ET on May 10, 2011 until midnight ET on May 17, 2011. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 11282805. The archived webcast will be available for 30 days at www.micromet.com.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.



CONTACT:

Micromet, Inc.
Jennifer Neiman, Director, Corporate Communications
240-235-0246
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.